Genomic Methods in Cancer Epigenetic Dysregulation

Similar documents
Enterprise Interest None

Precision medicine: How to exploit the growing knowledge on the evolving genomes of cells to improve cancer prevention and therapy.

Neuropathology Evening Session: Case 3

Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma

Epigene.cs: What is it and how it effects our health? Overview. Dr. Bill Stanford, PhD OFawa Hospital Research Ins.tute University of OFawa

Session 4 Rebecca Poulos

Out-Patient Billing CPT Codes

Session 6: Integration of epigenetic data. Peter J Park Department of Biomedical Informatics Harvard Medical School July 18-19, 2016

PRC2 crystal clear. Matthieu Schapira

The Cancer Genome Atlas & International Cancer Genome Consortium

Epigenetic programming in chronic lymphocytic leukemia

Histones modifications and variants

David Tamborero, PhD

Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser

Nature Genetics: doi: /ng.2995

Epigenetics and Toxicology

Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.

Clinical significance of genetic analysis in glioblastoma treatment

Session 4 Rebecca Poulos

Bivalent-chromatin and epigenetics alterations in Glioma

An epigenetic approach to understanding (and predicting?) environmental effects on gene expression

SUPPLEMENTARY FIGURES: Supplementary Figure 1

New drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna

Classification of Diffuse Gliomas: Progress, Pearls and Pitfalls. Rob Macaulay Neuropathologist, MCC October 21, 2017

Ahrim Youn 1,2, Kyung In Kim 2, Raul Rabadan 3,4, Benjamin Tycko 5, Yufeng Shen 3,4,6 and Shuang Wang 1*

Yue Wei 1, Rui Chen 2, Carlos E. Bueso-Ramos 3, Hui Yang 1, and Guillermo Garcia-Manero 1

The mutations that drive cancer. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge

Genomic analysis of childhood High grade glial (HGG) brain tumors

Juan Ma 1, Jennifer Dunlap 2, Lisong Shen 1, Guang Fan 2 1

Personalized Therapeutics The Power of Epigenetics. Company Overview. June 2014

Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges

NeoTYPE Cancer Profiles

About OMICS Group Conferences

Should Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!!

Supplemental Information. Molecular, Pathological, Radiological, and Immune. Profiling of Non-brainstem Pediatric High-Grade

ChromHMM Tutorial. Jason Ernst Assistant Professor University of California, Los Angeles

EZH2 Inhibitors as Novel Cancer Therapeutics!!!! Robert A. Copeland, Ph.D.! Epizyme, Inc.!!! 20 November 2014!

Gliomas in the 2016 WHO Classification of CNS Tumors

August 17, Dear Valued Client:

Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017

Introduction to Cancer Biology

Results and Discussion of Receptor Tyrosine Kinase. Activation

NeoTYPE Cancer Profiles

Pediatric Brain Tumor Research

Supplemental Figure 1. Genes showing ectopic H3K9 dimethylation in this study are DNA hypermethylated in Lister et al. study.

H3F3A K27M Mutation in Pediatric CNS Tumors. A Marker for Diffuse High-Grade Astrocytomas

Epigenetics. Lyle Armstrong. UJ Taylor & Francis Group. f'ci Garland Science NEW YORK AND LONDON

The Cancer Genome Atlas Pan-cancer analysis Katherine A. Hoadley

Studying recurrent somatic variations in high-grade glioma patients

Stem Cell Epigenetics

EPIGENOMICS PROFILING SERVICES

NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation

Cynthia Hawkins. Division of Pathology, Labatt Brain Tumour Research Centre, The Hospital for Sick Children, University of Toronto, Canada

Pan-cancer patterns of DNA methylation

Not IN Our Genes - A Different Kind of Inheritance.! Christopher Phiel, Ph.D. University of Colorado Denver Mini-STEM School February 4, 2014

Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ

September 20, Submitted electronically to: Cc: To Whom It May Concern:

A global assessment of cancer genomic alterations in epigenetic mechanisms

Structure and Function of Fusion Gene Products in. Childhood Acute Leukemia

FOLLICULAR LYMPHOMA- ILLUMINA METHYLATION. Jude Fitzgibbon

ARRO Case: Diffuse Intrinsic Pontine Glioma

Acute leukemia and myelodysplastic syndromes

The genetics of heterochromatin. in metazoa. mutations by means of X-ray irradiation" "for the discovery of the production of

The Epigenome Tools 2: ChIP-Seq and Data Analysis

Molecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC

Genomic Instability. Kent Nastiuk, PhD Dept. Cancer Genetics Roswell Park Cancer Institute. RPN-530 Oncology for Scientist-I October 18, 2016

RUNX1 and FPD/AML Translational Research. The Leukemia and Lymphoma Society / Babich Family Foundation Partnership. September 2016

Section D: The Molecular Biology of Cancer

Changing AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight

Reviewer #1 (Remarks to the Author)

Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous

Epigenomics. Ivana de la Serna Block Health Science

MicroRNA-29a Reveals Oncogenic Role on Myeloid Malignancies by Regulating DNMT3A

PROGRESS UPDATE. Evan T. Mandeville DIPG Research Fund

CBL and EZH2 as new molecular markers in MPN

Introduction to Systems Biology of Cancer Lecture 2

Pr D.Figarella-Branger Service d Anatomie Pathologique et de Neuropathologie, La Timone, Marseille UMR 911 Inserm, Université d Aix-Marseille

Dominic J Smiraglia, PhD Department of Cancer Genetics. DNA methylation in prostate cancer

NEW DEVELOPMENTS IN EPIGENETICS AND POTENTIAL CLINICAL APPLICATIONS

SUPPLEMENTARY INFORMATION

The Cancer Genome Atlas

Advances in Brain Tumor Research: Leveraging BIG data for BIG discoveries

Comparison of open chromatin regions between dentate granule cells and other tissues and neural cell types.

CRC 992 Symposium on Medical Epigenetics 2018

Cancer genetics

Testi del Syllabus. Testi in italiano. Resp. Did. SCHOEFTNER STEFAN Matricola: Docente SCHOEFTNER STEFAN, 6 CFU

Cancer and Tyrosine Kinase Inhibition

Registration Continental Breakfast. Histone Modifications and Cancer- Part 1

Dynamic reprogramming of DNA methylation in SETD2- deregulated renal cell carcinoma

Frontiers in Cancer Therapy. John Glod, M.D., Ph.D.

TARGETED THERAPY FOR CHILDHOOD CANCERS

Introduction of an NGS gene panel into the Haemato-Oncology MPN service

Computer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015

Clasificación Molecular del Cáncer de Próstata. JM Piulats

Enterprise Interest Thermo Fisher Scientific / Employee

An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer

Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma

Gene Expression DNA RNA. Protein. Metabolites, stress, environment

Human Genetics 542 Winter 2018 Syllabus

Genetics and Genomics in Medicine Chapter 10. Questions & Answers

Transcription:

Genomic Methods in Cancer Epigenetic Dysregulation Clara, Lyon 2018 Jacek Majewski, Associate Professor Department of Human Genetics, McGill University Montreal, Canada

A few words about my lab Genomics data analysis Statistics Bioinformatics Predictive models Classification Visualization Understanding Biology Hamid Nikhbath Rui Li Haifen Chen Simon Papillon

Genomics in Cancer How did we use to study cancer genes How genomics changed cancer research How genomics is used in cancer research illustrated by our own work Where are we today.

Philadelphia Chromosome 1959 Chromosome 9-22 translocation, specific to Chronic Myeloid Leukemia Results in the fusion of the BCR-ABL1 genes. Imatinib ABL kinase inhibitor - remains one of the most successful targeted cancer drugs available.

Other Genes -> pathways HRAS BRCA TP53 Pathways such as: signaling, DNA-damage repair, cellcycle.

Further progress Classical biology approaches to identify further components of candidate pathways and understand their function Those templates were also used in early versions of large-scale projects, such as TCGA

TCGA A prototype genomics approach. Use a global technologies to tackle multiple related diseases - cancer Outcome, dozens of new cancer genes Outcomes new cancer pathways Epigenetics as a new pathway: DNMTs, TET, EZH2, SETD2, KTMs, KDMs

The Epigenome

The Epigenome Our DNA is a faithful carrier of transgenerational inheritance. The Epigenome is the carrier of intragenerational inheritance Epigenetic patterns are faithfully transmitted along cell lineages Epigenome maintenance is necessary for cells to remember who they are. Epigenome dysregulation

Pediatric High Grade Glioma

Nada Jabado s lab

Adult Glioma one of the first TCGA projects Verhaak, Nature 2010

Children are not small adults Tumor type Tumor location within the brain Tumor history Tumor biology even when tumor looks the same Infrequent mutations in known adult GBM genes

H3.3K27M H3.3G34R Jeremy

The nature of the mutational partnership is determined by tumor location and and age of onset Cerebral Cortex: K36 IDH/TP53 SETD2 G34R/V H3.3/TP53 AGE CORTEX Thalamus H3.3/TP53 H3.3/FGFR H3.1/ACVR1 Brainstem (DIPG) H3.3/TP53 Cerebellum and Spine Midline: K27M

Evolution of Glioma Johnson et al. Science 2014

Pediatric Gliomas exhibit mutational partnerships: epigenetic + conventional Epigenetic Driver Appears earliest during tumor evolution An association of an epigenetic driver (e.g. H3K27M) and a more typical oncogenic mutation (e.g. TP53, ACVR1, FGFR1) is maintained throughout the tumor. Nikbahkt et. al Nat Communications 2016

Epigenetic Deregulation in Cancer Epigenetic Modifier Mutations: EZH2 SETD2, KDM6A IDH1/2 DNMT3A, MLL Melanoma Renal Cancer Glioma Leukemia Histone Mutations: H3F3A K27M, G34R, G34V HIST1H3B, HIST1H3C H3F3A G34W, G34L H3F3B K36M HIST1H3B K36M K36I HIST3 K27I HIST3 K36M Pediatric GBM mainly DIPG giant tumor of the bone chondroblastoma undifferentiated sarcoma found in some AML cases some head and neck cancers

What do histone mutations do?

K27M are gain of function mutations inhibit EZH2/PRC2 function Peter Lewis, David Allis, The Rockefeller University Lewis, P Science 2013

K27M is a dominant negative inhibitor of polycomb repressive complex 2 (PRC2) From Sturm et al., 2014

Genome Editing patient-derived GBM lines WT CRISPR H3K27M O/E EZH2 O/E EZH2 H3K27M CRISPR WT Inhibit EZH2 Inhibit EZH2

H3K27me3 Distribution Changes Resulting from H3K27M knock in De-repressed domain -> RNAseq

Effect of H3K27M mutation on the transcriptome Normal Cell x x x K27 me 3 K27me3 K27 me 3 K36me3 HAT K27M mutant x x K4 K27 me 3 DNA methylation me x3 DNA methylation K36me3

Glioma single cell RNA-seq Endothelial Astrocyte Oligodendrocyte Microglial Neurons Goals: Tumor Heterogeneity, Evolution, Cell of Origin

3D Chromatin Structure - HiC

Hi-C Contact Maps Chromosome 10

Comparative Hi-C enhancer Normal Brain K27M K27M K27M Histone WT Histone WT G34V G34R

Do we really need this? Whole Genome approaches are incredible tools to explore basic biology, including that of cancer WGS - DNA WGBS DNA methylation RNA-seq Expression ChIP-seq chromatin, TFBS HiC conformation Single Cell currently RNAseq, but other techniques are around the corner

Current Applications of Genomics in Personalized Medicine Mutation profiling, diagnosis WES, WGS, Panels DNA Methylation profiling Diagnostics - need implementation in the health care system

Personalized Medicine for Pediatric Glioblastoma Clinical testing for H3K27M antibody based test, liquid biopsy, CSF, etc. Currently, through research protocols, every pgbm case seen within our extensive network of collaborators goes through a batter of genomic assays. Personalized treatment? Palliation

Need Personalized Treatments!!!